BioNTech SE (BNTX)
103.10
+1.14
(+1.12%)
USD |
NASDAQ |
Dec 08, 13:58
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 24.51B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -37.31% |
| Valuation | |
| PE Ratio | 8.935 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 3.623 |
| Price to Book Value | 1.165 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.0102 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | -- |
Profile
| BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and small-molecule immunomodulators. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. COVID-19 vaccine Comirnaty is its first commercialized product. |
| URL | https://www.biontech.de |
| Investor Relations URL | https://investors.biontech.de/ |
| HQ State/Province | N/A |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | N/A |
| Next Earnings Release | Mar. 27, 2024 (est.) |
| Last Earnings Release | Nov. 06, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Jun. 02, 2022 |
Ratings
Profile
| BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and small-molecule immunomodulators. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. COVID-19 vaccine Comirnaty is its first commercialized product. |
| URL | https://www.biontech.de |
| Investor Relations URL | https://investors.biontech.de/ |
| HQ State/Province | N/A |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | N/A |
| Next Earnings Release | Mar. 27, 2024 (est.) |
| Last Earnings Release | Nov. 06, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Jun. 02, 2022 |